Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPRG4 in Sjögren's related dry eye disease
NCT06520202Phase 2Terminated
- Sponsor
- Lubris BioPharma
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human proteoglycan 4 in dry eye disease (DED), sponsored by Lubris BioPharma. Started Nov 2024; status: terminated.
02
Drugs
recombinant human proteoglycan 4
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06520202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520202.